SITC 2019

Gaylord National Hotel
& Convention Center

Nov. 6-10

NATIONAL HARBOR, MARYLAND

sitc

Society for Immunotherapy of Cancer

SITC 2019
Gaylord National Hotel & Convention Center Nov. 6-10
NATIONAL HARBOR, MARYLAND

A novel fully synthetic dual targeted Nectin-4/4-1BB *Bicycle*® peptide induces tumor localized 4-1BB agonism.

Nicholas Keen, CSO Bicycle Therapeutics

Disclaimer

This presentation has been prepared by an affiliate of Bicycle Therapeutics plc ("we," "us," "our," "Bicycle" or the "Company"), and is made for informational purposes only and not for any other purpose. Certain information contained in this presentation or made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may" "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding plans or strategies, our current and prospective product candidates and planned clinical trials and preclinical activities.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials, the risk that we may not realize the intended benefits our technology, including that we may not identify and develop additional product candidates for our pipeline, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results will not be replicated or will not continue in ongoing or future studies or trials and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our final prospectus for our initial public offering filed with the Securities and Exchange Commission on May 23, 2019, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Conflict of interest statement

- I am an employee of Bicycle Therapeutics Inc.
- I am a stockholder in Bicycle Therapeutics plc.

Bicycle Therapeutics

- Founded by Sir Gregory Winter & Prof. Christian Heinis
- UK & US based (Cambridge, UK; Boston, USA)
- Internal focus on Oncology
  - BT1718 – Phase 1/2a (Cancer Research UK)
  - 2nd Generation *Bicycle Toxin Conjugates*® in pre-clinical development
  - ***Bicycle*® immune cell modulators**

Bicycles®: a new therapeutic modality

- Structurally constrained Bicyclic peptides, chemically synthesised, low MWt (1.5-2kDa)
- Large binding footprint allowing targeting of protein-protein interactions
- Small molecule like PK and tumor penetration, renal excretion







EphA2 binding *Bicycle*

Proprietary screening platform: *Bicycles*® optimised using phage display and medicinal chemistry, informed by structural biology

Bicycle Phage Display



Optimize binder & capture IP

Natural Amino Acids

Structural Biology



Peptide & Medicinal Chemistry





Histidine
Ki=11nM

3,3-diphenylalanine (3,3-DPA)
Ki=0.9nM

Dial in desired drug-like properties and PK profile

Non-natural Amino Acids

CD137 activation leads to potent anti-tumor response through diverse mechanisms



T-cells: Sustained activation, cytokine secretion, induced growth and survival, restoration of effector functions

Dendritic cells: Activation and cytokine secretion

Macrophages: Activation and cytokine secretion

NK cells: Activation and cytokine secretion, increase in ADCC

- Highly validated IO target – roles in key steps in cancer immune cycle
- Expressed on, and stimulates T-cells, NKT, NK, Dendritic cells, Macrophages, B cells and neutrophils
- Urelumab, a superagonistic anti-CD137 mAb effective as a single agent in clinic, but utility limited by hepatotoxicity and long $t_{1/2}$
- A tumor antigen specific agonist could provide efficacy without systemic toxicity

Tumor/CD137 binding *Bicycles*® as tumor-targeted immune cell agonists (TICAs)



CD137 is member of the TNF superfamily & requires clustering for activation



"All natural" phage peptide
KD = 67nM (Wild Type: WT)

Chemically optimised
KD = 5nM (High Affinity: HA)





Nectin-4 (PVRL4): Rationale as a tumor antigen

- Nectin-4: cell adhesion molecule; widely expressed during development with restricted expression in adult normal tissue
- Over expressed in numerous tumors of high unmet need; highest frequency in bladder, breast, and pancreatic, but also in lung and esophageal cancers
- Internal work demonstrates co-expression of CD137 in significant subsets of Nectin-4 positive tumors
- Precedented target for bladder cancer; Enfortumab Vedotin (MMAE Nectin-4 ADC) has breakthrough therapy in post platin, post CI bladder cancer
  - ORR 42% (N=125)
- Building internal expression/diagnostic capability



Challita-Eid et al Cancer Res 76: 3003-3013 (2016)



Rabet et al Annals of Oncology 28:769-776 (2017)

Nectin-4/CD137 *Bicycles*® are precisely engineered tumor antigen specific CD137 agonists







Human PBMC / tumor cell co-culture

Bicycle® TICAs enable optimum spacing compared to bulkier biologics

- Typical immune cell receptor complex spacing ~140Å
- Most biologics far larger, meaning significant steric restraints



Bicycle® TICAs are ~30x smaller than other targeted agonists

***Bicycle* TICA**



~6kDa

Anti-FAP IgG-CD137L fusion Roche RG7826



~185kDa

Anti-Her2 IgG-anti-CD137 anticalin fusion Pieris PRS-343

~190kDa

Chemical nature of platform allows rapid "dialing in" of properties



>90 Nectin-4 TICA molecules synthesized in combinatorial manner

Reporter cell assay data for 30 Nectin-4/CD137 TICAs in co-culture with HT1376



PK can be "tuned"



50% Target coverage is the line above which [Plasma,u] is maintained over [EC50,u]

Molecules are selectively retained in Nectin-4 expressing tumors.



Predicted human PK parameters

BCY	in vitro EC50(nM)	$t_{1/2}$(h)	CLp (mL/min/kg)	Veff (L/kg)
BCY10572	0.59	0.83	13	0.91
BT7480	0.47	12	1.2	1.2

Intermittent dosing of BT7480 leads to a robust anti-tumor activity









#SITC2019

Intermittent dosing of BT7480 leads to an increase in CD8+ T cells without elevations of liver enzymes









Note: Q3D in mouse equivalent to once per week in human

- Anti-tumor activity of BT7480 was assessed in Nectin-4 overexpressing (engineered) CT26 syngeneic mouse model
- Several responders in both QD and Q3D dosing groups

- By D15, CD8+ T cell population increases significantly
- By D15, No significant changes in AST, ALT and APHOS

Summary

- Bicycle are building a new generation of chemically synthetic (NCE) tumor antigen targeted CD137 agonists.
- These are much smaller than biologics, rapidly tumor penetrant, and tailored to the geometry of the immune synapse .
- Potency and pharmacokinetics are “tunable.”
- Our lead Nectin-4/CD137 TICA (BT7480) induces complete regressions and resistance to re-challenge in immune competent models with intermittent dosing.
- Approach is generalizable.



See Posters **P782**, **P794 Saturday!**

Thanks!

Bicycle US

Bicycle UK